Senior Recital: Claire Marie Pappas, soprano

This recital is presented in partial fulfillment of requirements for the degree Bachelor of Music in Music Education. Ms. Pappas studies voice with Jana Young.https://digitalcommons.kennesaw.edu/musicprograms/2130/thumbnail.jp

Vocal Jazz Combo and Jazz Ensemble III Debut Concert

This KSU School of Music Debut Concert features the Vocal Jazz Combo under the direction of Karla Harris, Artist-in-Residence in Vocal Jazz, and Jazz Ensemble III under the direction of Rob Opitz, Artist-in-Residence in Jazz Trumpet.https://digitalcommons.kennesaw.edu/musicprograms/2112/thumbnail.jp

Women\u27s Choir and Wind Symphony

This KSU School of Music performance features Women\u27s Choir, conducted by Alison Mann, and Wind Symphony, conducted by Debra Traficante and guest conductor, Archie Birkner IV.https://digitalcommons.kennesaw.edu/musicprograms/2031/thumbnail.jp

Senior Recital: Joseph Donohue, percussion

This recital is presented in partial fulfillment of requirements for the degree Bachelor of Music in Performance. Mr. Donohue studies percussion with John Lawless.https://digitalcommons.kennesaw.edu/musicprograms/2086/thumbnail.jp

2018 Voice Honors Recital

KSU School of Music presents the 2018 Voice Honors Recital.https://digitalcommons.kennesaw.edu/musicprograms/2023/thumbnail.jp

Choral Ensembles Spring Concert

This Kennesaw State University School of Music performance features Chamber Singers, Men\u27s Ensemble, and University Chorale directed by Dr. Leslie Blackwell, Director of Choral Activities and Professor of Music and Music Education.https://digitalcommons.kennesaw.edu/musicprograms/2054/thumbnail.jp

Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both

Importance: Age-related macular degeneration (AMD) is a common cause of irreversible vision loss among individuals older than 50 years. Although considerable advances have been made in our understanding of AMD genetics, the differential effects of major associated loci on disease manifestation and progression may not be well characterized. Objective: To elucidate the specific associations of the 2 most common genetic risk loci for AMD, the CFH-CFHR5 locus on chromosome 1q32 (Chr1) and the ARMS2/HTRA1 locus on chromosome 10q26 (Chr10)-independent of one another and in combination-with time to conversion to late-stage disease and to visual acuity loss. Design, Setting, and Participants: This case series study included 502 individuals who were homozygous for risk variants at both Chr1 and Chr10 (termed Chr1&10-risk) or at either Chr1 (Chr1-risk) or Chr10 (Chr10-risk) and who had enrolled in Genetic and Molecular Studies of Eye Diseases at the Sharon Eccles Steele Center for Translational Medicine between September 2009 and March 2020. Multimodal imaging data were reviewed for AMD staging, including grading of incomplete and complete retinal pigment epithelium and outer retinal atrophy. Main Outcomes and Measures: Hazard ratios and survival times for conversion to any late-stage AMD, atrophic or neovascular, and associated vision loss of 2 or more lines. Results: In total, 317 participants in the Chr1-risk group (median [IQR] age at first visit, 75.6 [69.5-81.7] years; 193 women [60.9%]), 93 participants in the Chr10-risk group (median [IQR] age at first visit, 77.5 [72.2-84.2] years; 62 women [66.7%]), and 92 participants in the Chr1&10-risk group (median [IQR] age at first visit, 71.7 [68.0-76.3] years; 62 women [67.4%]) were included in the analyses. After adjusting for age and AMD grade at first visit, compared with 257 participants in the Chr1-risk group, 56 participants in the Chr1&10-risk group (factor of 3.3 [95% CI, 1.6-6.8]; P < .001) and 58 participants in the Chr10-risk group (factor of 2.6 [95% CI, 1.3-5.2]; P = .007) were more likely to convert to a late-stage phenotype during follow-up. This difference was mostly associated with conversion to macular neovascularization, which occurred earlier in participants with Chr1&10-risk and Chr10-risk. Eyes in the Chr1&10-risk group (median [IQR] survival, 5.7 [2.1-11.1] years) were 2.1 (95% CI, 1.1-3.9; P = .03) times as likely and eyes in the Chr10-risk group (median [IQR] survival, 6.3 [2.7-11.3] years) were 1.8 (95% CI, 1.0-3.1; P = .05) times as likely to experience a visual acuity loss of 2 or more lines compared with eyes of the Chr1-risk group (median [IQR] survival, 9.4 [4.1-* (asterisk indicates event rate did not reach 75%)] years). Conclusions and Relevance: These findings suggest differential associations of the 2 major AMD-related risk loci with structural and functional disease progression and suggest distinct underlying biological mechanisms associated with these 2 loci. These genotype-phenotype associations may warrant consideration when designing and interpreting AMD research studies and clinical trials

Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis

BACKGROUND: The Infectious Diseases Society of America published in 2000 practical guidelines for the management of cryptococcosis. However, treatment strategies have not been fully validated in the various clinical settings due to exclusion criteria during therapeutic trials. We assessed here the optimal therapeutic strategies for severe cryptococcosis using the observational prospective CryptoA/D study after analyzing routine clinical care of cryptococcosis in university or tertiary care hospitals. METHODOLOGY/PRINCIPAL FINDINGS: Patients were enrolled if at least one culture grew positive with Cryptococcus neoformans. Control of sterilization was warranted 2 weeks (Wk2) and 3 months (Mo3) after antifungal therapy onset. 208 HIV-positive or -negative adult patients were analyzed. Treatment failure (death or mycological failure) at Wk2 and Mo3 was the main outcome measured. Combination of amphotericin B+flucytosine (AMB+5FC) was the best regimen for induction therapy in patients with meningoencephalitis and in all patients with high fungal burden and abnormal neurology. In those patients, treatment failure at Wk2 was 26% in the AMB+5FC group vs. 56% with any other treatments (p<0.001). In patients treated with AMB+5FC, factors independently associated with Wk2 mycological failure were high serum antigen titer (OR [95%CI] = 4.43[1.21-16.23], p = 0.025) and abnormal brain imaging (OR = 3.89[1.23-12.31], p = 0.021) at baseline. Haematological malignancy (OR = 4.02[1.32-12.25], p = 0.015), abnormal neurology at baseline (OR = 2.71[1.10-6.69], p = 0.030) and prescription of 5FC for less than 14 days (OR = 3.30[1.12-9.70], p = 0.030) were independently associated with treatment failure at Mo3. CONCLUSION/SIGNIFICANCE: Our results support the conclusion that induction therapy with AMB+5FC for at least 14 days should be prescribed rather than any other induction treatments in all patients with high fungal burden at baseline regardless of their HIV serostatus and of the presence of proven meningoencephalitis

Chamber Singers, Men\u27s Ensemble and University Chorale, Requiem for the Living

KSU School of Music presents Chamber Singers, Men\u27s Ensemble and University Chorale directed by Dr. Leslie Blackwell, Director of Choral Activities and Professor of Music and Music Education.https://digitalcommons.kennesaw.edu/musicprograms/2033/thumbnail.jp

Dr. Bobbie Bailey & Family Performance Center Anniversary Celebration

The School of Music is proud to welcome back to campus several of our esteemed alumni for a special recital as part of the Bailey Performance Center 10th anniversary celebration! The School of Music celebrates the opening of the Bailey Performance Center with featured performances by the KSU Wind Ensemble Brass and Percussion, Symphony Orchestra, Chamber Singers, University Chorale and Chamber Singers Alumni Choir, along with pianist Robert Henry, soprano Jana Young, and more!https://digitalcommons.kennesaw.edu/musicprograms/1969/thumbnail.jp